CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Wedbush Adjusts Price Target on Hemab Therapeutics to $64 From $55, Keeps Outperform Rating

Positive
AI Analysis

Summary

Wedbush increased its price target on Hemab Therapeutics to $64 from $55 while maintaining an Outperform rating.

Importance:2/10
Sentiment:
0.60
price_targetanalyst_ratingvaluation
Related Companies

Read the original article

Published by yahoo_finance on August 11, 2026 3:48 PM

Read Original